Clinical Trials Logo

Clinical Trial Summary

To demonstrate that Robotic-Assisted partial nephrectomy is superior to Open partial nephrectomy in reducing the number of 30 day post-operative complications (Clavien-Dindo Type I-V) for patients with intermediate to high complexity kidney tumors.


Clinical Trial Description

Partial nephrectomy is the surgical removal of a kidney tumor while unaffected tissue remains intact so that the kidney function is maintained as far as possible. The more radical procedure would be the complete removal of the kidney, which is not examined in this trial. Surgery will be randomized either to an open technique involving a large incision or the robotic assisted technique with a few small incisions (keyhole surgery). With robotic assisted surgery the movements of the surgeon are translated into the movement of the instruments. It is not clear which of the two procedures, open or robotic assisted, has less complications. It is expected that these are different due to the different level of invasiveness and the level of direct access to the organ. This study aims to show that robotic assisted surgery results in less complications than open surgery. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03849820
Study type Interventional
Source Intuitive Surgical
Contact
Status Terminated
Phase N/A
Start date March 12, 2019
Completion date October 25, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT00531284 - Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma Phase 1/Phase 2
Recruiting NCT05842044 - NSAID Use After Robotic Partial Nephrectomy Phase 2
Recruiting NCT05387863 - Decision Aid (DA) for Renal Patients N/A
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Withdrawn NCT03390413 - Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer N/A
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Active, not recruiting NCT03203473 - Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) Phase 2
Suspended NCT04115254 - Stereotactic Magnetic Resonance Guided Radiation Therapy N/A
Enrolling by invitation NCT02609269 - Decipher Genomics Resource for Intelligent Discovery
Terminated NCT01453595 - BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) Phase 1/Phase 2
Completed NCT01444456 - Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia N/A
Completed NCT02811250 - Stereotactic Radiotherapy for Renal Cancers N/A
Completed NCT00398814 - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers Phase 1
Completed NCT00399152 - Perifosine + Sunitinib Malate for Patients With Advanced Cancers Phase 1
Completed NCT00458536 - Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF Phase 1/Phase 2
Recruiting NCT03693014 - A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors Phase 2
Completed NCT00418496 - Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma Phase 1